The US launch of Veloxis’ drug Envarsus XR, used to prevent organ rejection in transplantees, helped the company to quadruple revenue in 2016. It gives the management team, led by CEO Craig Collard, cause for optimism for 2017.
“It has been a bit of a transition year for Veloxis. I joined the company in December 2015, and since then we have replaced the entire management team and restructured the organization. In the middle of all that, we have also launched Envarsus XR in the US. So a lot has happened, but I feel like the business is slowly accelerating,” Craig Collard says in an interview with MedWatch.